$ARVN Receives FDA clearance to Proceed for its IND Application for PROTAC Therapy to Treat Patients with Metastatic CastrationResistant Prostate CancerExpects Enrollment of Phase 1 Trial to Begin in Q1 2019

$ARVN Receives FDA clearance to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer Expects Enrollment of Phase 1 Trial to Begin in Q1 2019

17:02 EST 4 Jan 2019 | Odi Bruckman

$ARVN Receives FDA clearance to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer Expects Enrollment of Phase 1 Trial to Begin in Q1 2019

More From BioPortfolio on "$ARVN Receives FDA clearance to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer Expects Enrollment of Phase 1 Trial to Begin in Q1 2019"